Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Operating cash flow minus capital expenditures
Latest
$-70.46M
↓ 107% vs avg
Percentile
P13
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-33.97M
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $-70.46M | +3.8% |
| 2024 | $-73.24M | -19.2% |
| 2023 | $-61.42M | -87.9% |
| 2022 | $-32.69M | -69.2% |
| 2021 | $-19.32M | -115.0% |
| 2020 | $-8.99M | +59.2% |
| 2019 | $-22.02M | -150.8% |
| 2018 | $-8.78M | +0.1% |
| 2017 | $-8.79M | - |